Oral innate immunity in HIV infection in HAART era

Journal of Oral Pathology and Medicine

Volumn 45, Issue 1, 2016, Pages 3-8

  Nittayananta, Wipawee ^a   Tao, Renchuan ^b   Jiang, Lanlan ^b   Peng, Yuanyuan ^b   Huang, Yuxiao ^b  

^a PRINCE OF SONGKLA UNIVERSITY   (Thailand)

^b GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

Antimicrobial peptides; Cytokines; Defensins; Highly active antiretroviral therapy; Human immunodeficiency virus; Oral innate immunity; Secretory leukocyte protease inhibitor

Indexed keywords

ALPHA DEFENSIN; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BETA DEFENSIN; C TYPE LECTIN RECEPTOR; DEFENSIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LECTIN RECEPTOR; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; POLYPEPTIDE ANTIBIOTIC AGENT; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR; THETA DEFENSIN; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT;

ADAPTIVE IMMUNITY; CANDIDA ALBICANS; CANDIDIASIS; CD4 LYMPHOCYTE COUNT; CELL ADHESION; CELL JUNCTION; CYTOKINE RELEASE; EPITHELIUM CELL; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN HERPESVIRUS 6; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION; INNATE IMMUNITY; LONG TERMINAL REPEAT; MIXED INFECTION; MOUTH MUCOSA; NONHUMAN; OPPORTUNISTIC INFECTION; ORAL INNATE IMMUNITY; PERIODONTAL DISEASE; PRIORITY JOURNAL; REVIEW; VIRUS LOAD; AIDS RELATED COMPLEX; DRUG EFFECTS; HEALTH; IMMUNOLOGY; MUCOSAL IMMUNITY; PROCEDURES;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-INFECTIVE AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HIV INFECTIONS; HUMANS; IMMUNITY, INNATE; IMMUNITY, MUCOSAL; MOUTH MUCOSA; ORAL HEALTH;

EID: 84955492084     PISSN: 09042512     EISSN: 16000714     Source Type: Journal    
DOI: 10.1111/jop.12304     Document Type: Review

References (66)

1. Challacombe SJ, Naglik JR. The effects of HIV infection on oral mucosal immunity. Adv Dent Res 2006; 19: 29-35.
2. Modlin RL. Innate immunity: ignored for decades, but not forgotten. J Invest Dermatol 2012; 132: 882-6.
3. Nittayananta W, Kemapunmanus M, Amornthatree K, Talungchit S, Sriplung H. Oral human beta-defensin 2 in HIV-infected subjects with long-term use of antiretroviral therapy. J Oral Pathol Med 2013; 42: 53-60.
4. Leigh JE, Shetty K, Fidel PL Jr. Oral opportunistic infections in HIV-positive individuals: review and role of mucosal immunity. AIDS Patient Care STDS 2004; 18: 443-56.
5. Challacombe SJ, Fidel PL Jr, Tugizov S, Tao L, Wahl SM. HIV infection and specific mucosal immunity: workshop 4B. Adv Dent Res 2011; 23: 142-51.
6. Walker DM. Oral mucosal immunology: an overview. Ann Acad Med Singapore 2004; 33: 27-30.
7. Fabian TK, Hermann P, Beck A, Fejerdy P, Fabian G. Salivary defense proteins: their network and role in innate and acquired oral immunity. Int J Mol Sci 2012; 13: 4295-320.
8. Squier CA, Kremer MJ. Biology of oral mucosa and esophagus. J Natl Cancer Inst Monogr 2001: 7-15.
9. Stoitzner P, Romani N. Langerin, the "Catcher in the Rye": an important receptor for pathogens on Langerhans cells. Eur J Immunol 2011; 41: 2526-9.
10. Nittayananta W, Mitarnun W, Talungchit S, Sriplung H. Changes in oral cytokeratin expression in HIV-infected subjects with long-term use of HAART. Oral Dis 2012; 18: 793-801.
11. Bafica A, Scanga CA, Schito M, Chaussabel D, Sher A. Influence of coinfecting pathogens on HIV expression: evidence for a role of Toll-like receptors. J Immunol 2004; 172: 7229-34.
12. Lester RT, Yao XD, Ball TB, et al. Toll-like receptor expression and responsiveness are increased in viraemic HIV-1 infection. Aids 2008; 22: 685-94.
13. Lin AL, Johnson DA, Stephan KT, Yeh CK. Alteration in salivary function in early HIV infection. J Dent Res 2003; 82: 719-24.
14. Lin AL, Johnson DA, Sims CA, Stephan KT, Yeh C-K. Salivary gland function in HIV-infected patients treated with highly active antiretroviral therapy (HAART). Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006; 102: 318-24.
15. Egusa H, Nikawa H, Makihira S, Yatani H, Hamada T. In vitro mechanisms of interleukin-8-mediated responses of human gingival epithelial cells to Candida albicans infection. Int J Med Microbiol 2006; 296: 301-11.
16. Muller F, Holberg-Petersen M, Rollag H, Degre M, Brandtzaeg P, Froland SS. Nonspecific oral immunity in individuals with HIV infection. J Acquir Immune Defic Syndr 1992; 5: 46-51.
17. Challacombe SJ, Sweet SP. Salivary and mucosal immune responses to HIV and its co-pathogens. Oral Dis 1997; 3(Suppl 1): S79-84.
18. Muller F, Froland SS, Brandtzaeg P, Fagerhol MK. Oral candidiasis is associated with low levels of parotid calprotectin in individuals with infection due to human immunodeficiency virus. Clin Infect Dis 1993; 16: 301-2.
19. Mandel ID, Barr CE, Turgeon L. Longitudinal study of parotid saliva in HIV-1 infection. J Oral Pathol Med 1992; 21: 209-13.
20. Lin AL, Johnson DA, Patterson TF, et al. Salivary anticandidal activity and saliva composition in an HIV-infected cohort. Oral Microbiol Immunol 2001; 16: 270-8.
21. Oppenheim FG, Xu T, McMillian FM, et al. Histatins, a novel family of histidine-rich proteins in human parotid secretion. Isolation, characterization, primary structure, and fungistatic effects on Candida albicans. J Biol Chem 1988; 263: 7472-7.
22. Xu H, Wang X, Veazey RS. Mucosal immunology of HIV infection. Immunol Rev 2013; 254: 10-33.
23. Nittayananta W, Kemapunmanus M, Yangngam S, Talungchit S, Sriplung H. Expression of oral secretory leukocyte protease inhibitor in HIV-infected subjects with long-term use of antiretroviral therapy. J Oral Pathol Med 2013; 42: 208-15.
24. Jana NK, Gray LR, Shugars DC. Human immunodeficiency virus type 1 stimulates the expression and production of secretory leukocyte protease inhibitor (SLPI) in oral epithelial cells: a role for SLPI in innate mucosal immunity. J Virol 2005; 79: 6432-40.
25. Lin AL, Johnson DA, Stephan KT, Yeh CK. Salivary secretory leukocyte protease inhibitor increases in HIV infection. J Oral Pathol Med 2004; 33: 410-6.
26. Clifford GM, Polesel J, Rickenbach M, et al. Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst 2005; 97: 425-32.
27. Gillison ML. Oropharyngeal cancer: a potential consequence of concomitant HPV and HIV infection. Curr Opin Oncol 2009; 21: 439-44.
28. Nittayananta W, Talungchit S, Jaruratanasirikul S, et al. Effects of long-term use of HAART on oral health status of HIV-infected subjects. J Oral Pathol Med 2010; 39: 397-406.
29. Quinones-Mateu ME, Lederman MM, Feng Z, et al. Human epithelial beta-defensins 2 and 3 inhibit HIV-1 replication. Aids 2003; 17: F39-48.
30. Daniels TE, Greenspan D, Greenspan JS, et al. Absence of Langerhans cells in oral hairy leukoplakia, an AIDS-associated lesion. J Invest Dermatol 1987; 89: 178-82.
31. Walling DM, Flaitz CM, Hosein FG, Montes-Walters M, Nichols CM. Effect of Epstein-Barr virus replication on Langerhans cells in pathogenesis of oral hairy leukoplakia. J Infect Dis 2004; 189: 1656-63.
32. Chou LL, Epstein J, Cassol SA, West DM, He W, Firth JD. Oral mucosal Langerhans' cells as target, effector and vector in HIV infection. J Oral Pathol Med 2000; 29: 394-402.
33. Neutra MR, Mantis NJ, Kraehenbuhl JP. Collaboration of epithelial cells with organized mucosal lymphoid tissues. Nat Immunol 2001; 2: 1004-9.
34. Palefsky J. Human papillomavirus-related disease in people with HIV. Curr Opin HIV AIDS 2009; 4: 52-6.
35. Steubesand N, Kiehne K, Brunke G, et al. The expression of the beta-defensins hBD-2 and hBD-3 is differentially regulated by NF-kappaB and MAPK/AP-1 pathways in an in vitro model of Candida esophagitis. BMC Immunol 2009; 10: 36.
36. Chang HT, Tsai PW, Huang HH, Liu YS, Chien TS, Lan CY. LL37 and hBD-3 elevate the beta-1, 3-exoglucanase activity of Candida albicans Xog1p, resulting in reduced fungal adhesion to plastic. Biochem J 2012; 441: 963-70.
37. Netea MG, Brown GD, Kullberg BJ, Gow NA. An integrated model of the recognition of Candida albicans by the innate immune system. Nat Rev Microbiol 2008; 6: 67-78.
38. Bryant C, Fitzgerald KA. Molecular mechanisms involved in inflammasome activation. Trends Cell Biol 2009; 19: 455-64.
39. Weindl G, Wagener J, Schaller M. Epithelial cells and innate antifungal defense. J Dent Res 2010; 89: 666-75.
40. Mora-Montes HM, Netea MG, Ferwerda G, et al. Recognition and blocking of innate immunity cells by Candida albicans chitin. Infect Immun 2011; 79: 1961-70.
41. Dongari-Bagtzoglou A, Villar CC, Kashleva H. Candida albicans-infected oral epithelial cells augment the anti-fungal activity of human neutrophils in vitro. Med Mycol 2005; 43: 545-9.
42. Netea MG, Sutmuller R, Hermann C, et al. Toll-like receptor 2 suppresses immunity against Candida albicans through induction of IL-10 and regulatory T cells. J Immunol 2004; 172: 3712-8.
43. De Smet K, Contreras R. Human antimicrobial peptides: defensins, cathelicidins and histatins. Biotechnol Lett 2005; 27: 1337-47.
44. Hua X, Yuan X, Tang X, Li Z, Pflugfelder SC, Li DQ. Human corneal epithelial cells produce antimicrobial peptides LL-37 and beta-defensins in response to heat-killed Candida albicans. Ophthalmic Res 2014; 51: 179-86.
45. Khan SA, Fidel PL Jr, Thunayyan AA, Varlotta S, Meiller TF, Jabra-Rizk MA. Impaired histatin-5 levels and salivary antimicrobial activity against in hiv infected individuals. J AIDS Clin Res 2013; 4. doi:10.4172/2155-6113.1000193
46. Hazlett L, Wu M. Defensins in innate immunity. Cell Tissue Res 2011; 343: 175-88.
47. Hazrati E, Galen B, Lu W, et al. Human alpha- and beta-defensins block multiple steps in herpes simplex virus infection. J Immunol 2006; 177: 8658-66.
48. Yasin B, Wang W, Pang M, et al. Theta defensins protect cells from infection by herpes simplex virus by inhibiting viral adhesion and entry. J Virol 2004; 78: 5147-56.
49. Triantos D, Horefti E, Paximadi E, et al. Presence of human herpes virus-8 in saliva and non-lesional oral mucosa in HIV-infected and oncologic immunocompromised patients. Oral Microbiol Immunol 2004; 19: 201-4.
50. Kis A, Feher E, Gall T, et al. Epstein-Barr virus prevalence in oral squamous cell cancer and in potentially malignant oral disorders in an eastern Hungarian population. Eur J Oral Sci 2009; 117: 536-40.
51. Silverberg MJ, Chao C, Leyden WA, et al. HIV infection and the risk of cancers with and without a known infectious cause. Aids 2009; 23: 2337-45.
52. Mwakigonja AR, Kaaya EE, Heiden T, et al. Tanzanian malignant lymphomas: WHO classification, presentation, ploidy, proliferation and HIV/EBV association. BMC Cancer 2010; 10: 344.
53. Burbelo PD, Kovacs JA, Wagner J, et al. The cancer-associated virus landscape in HIV patients with oral hairy leukoplakia, Kaposi's sarcoma, and non-Hodgkin lymphoma. AIDS Res Treat 2012; 2012: 634523.
54. Walling DM, Flaitz CM, Nichols CM, Hudnall SD, Adler-Storthz K. Persistent productive Epstein-Barr virus replication in normal epithelial cells in vivo. J Infect Dis 2001; 184: 1499-507.
55. Campisi G, Panzarella V, Giuliani M, et al. Human papillomavirus: its identity and controversial role in oral oncogenesis, premalignant and malignant lesions (review). Int J Oncol 2007; 30: 813-23.
56. Levinson P, Kaul R, Kimani J, et al. Levels of innate immune factors in genital fluids: association of alpha defensins and LL-37 with genital infections and increased HIV acquisition. Aids 2009; 23: 309-17.
57. Raj PA, Dentino AR. Current status of defensins and their role in innate and adaptive immunity. FEMS Microbiol Lett 2002; 206: 9-18.
58. Brady LJ, Walker C, Oxford GE, Stewart C, Magnusson I, McArthur W. Oral diseases, mycology and periodontal microbiology of HIV-1-infected women. Oral Microbiol Immunol 1996; 11: 371-80.
59. Tsang CS, Samaranayake LP. Predominant cultivable subgingival microbiota of healthy and HIV-infected ethnic Chinese. APMIS 2001; 109: 117-26.
60. Patel M, Coogan M, Galpin JS. Periodontal pathogens in subgingival plaque of HIV-positive subjects with chronic periodontitis. Oral Microbiol Immunol 2003; 18: 199-201.
61. Michailidis C, Giannopoulos G, Vigklis V, Armenis K, Tsakris A, Gargalianos P. Impaired phagocytosis among patients infected by the human immunodeficiency virus: implication for a role of highly active anti-retroviral therapy. Clin Exp Immunol 2012; 167: 499-504.
62. Myint M, Yuan ZN, Schenck K. Reduced numbers of Langerhans cells and increased HLA-DR expression in keratinocytes in the oral gingival epithelium of HIV-infected patients with periodontitis. J Clin Periodontol 2000; 27: 513-9.
63. Segundo TK, Souto GR, Mesquita RA, Costa FO. Langerhans cells in periodontal disease of HIV- and HIV+ patients undergoing highly active antiretroviral therapy. Braz Oral Res 2011; 25: 255-60.
64. Cauda R, Tacconelli E, Tumbarello M, et al. Role of protease inhibitors in preventing recurrent oral candidosis in patients with HIV infection: a prospective case-control study. J Acquir Immune Defic Syndr 1999; 21: 20-5.
65. McCullough M, Jaber M, Barrett AW, Bain L, Speight PM, Porter SR. Oral yeast carriage correlates with presence of oral epithelial dysplasia. Oral Oncol 2002; 38: 391-3.
66. Field EA, Field JK, Martin MV. Does Candida have a role in oral epithelial neoplasia? J Med Vet Mycol 1989; 27: 277-94.